Immunotherapeutics for a better tomorrow

Company Overview

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, our influenza vaccine candidate, has unique characteristics that stimulate multiple arms of the immune system and offers the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine. By leveraging the complementary attributes of its proprietary technology platforms, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including both acute and chronic infections and cancer.



HepTcell is an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (“HBV”). It is designed to drive CD4+ and CD8+ T-cell responses against all HBV genotypes in patients of all ethnic backgrounds. Stimulating T cell responses in chronically infected HBV patients has been challenging because chronic infection with HBV strongly diminishes T cell immunity directed against the virus.


ALT-702 is a targeted tumor immunostimulant product candidate that comprises of a highly potent and selective dual TLR7/8 agonist conjugate designed to overcome the safety limitations of other tumor immune stimulants. ALT-702 is being developed to act locally to reverse local immunosuppression within the tumor microenvironment and stimulate antitumor immune responses. ALT-702 also has the potential to synergize with other local and systemic treatment modalities. Altimmune is currently progressing with the preclinical development plan.


NasoVAX™, our most advanced product candidate is an intranasally administered recombinant influenza vaccine, uses an adenovector to achieve expression of the influenza antigen in the target cell, thereby potentially stimulating a broader and more rapid immune response than traditional influenza vaccines.


NasoShield™, a first-in-class anthrax vaccine designed to provide rapid, stable protection after intranasal administration is being developed with the support of the U.S. Biomedical Advanced Research and Development Authority. NasoShield is based on our RespirVec technology to provide protection following intranasal administration as opposed to multiple injections.